Advances in Alzheimer's Disease

Alzheimer’s disease (AD), also known as Alzheimer disease, accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care and behavioral. As a person’s condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years.

 

In the present book, ten typical literatures about Alzheimer’s disease published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, neurology, genetics, ect. We hope this book can demonstrate advances in Alzheimer’s disease as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    A Meta-Analysis of Prospective Studies on the Role of Physical Activity and the Prevention of Alzheimer’s Disease in Older Adults
  • Chapter 2
    Immune Responses in Rapidly Progressive Dementia: A Comparative Study of Neuroinflammatory Markers in Creutzfeldt-Jakob Disease, Alzheimer’s Disease and Multiple Sclerosis
  • Chapter 3
    Lifetime Expectancy and Quality-Adjusted Life-Year in Alzheimer’s Disease with and without Cerebrovascular Disease: Effects of Nursing Home Replacement and Donepezil Administration – A Retrospective Analysis in the Tajiri Project
  • Chapter 4
    SNAP-25 is a Promising Novel Cerebrospinal Fluid Biomarker for Synapse Degeneration in Alzheimer ’s Disease
  • Chapter 5
    Alzheimer’s Disease Assessment Scale–Cognitive Subscale Variants in Mild Cognitive Impairment and Mild Alzheimer’s Disease: Change Over Time and the Effect of Enrichment Strategies
  • Chapter 6
    Assessing THK523 Selectivity for Tau Deposits in Alzheimer’s Disease and Non-Alzheimer’s Disease Tauopathies
  • Chapter 7
    Evidence That the Presynaptic Vesicle Protein CSPalpha is a Key Player in Synaptic Degeneration and Protection in Alzheimer’s Disease
  • Chapter 8
    Platelet Dysfunction in Hypercholesterolemia Mice, Two Alzheimer’s Disease Mouse Models and in Human Patients with Alzheimer’s Disease
  • Chapter 9
    Which Medical and Social Decision Topics Are Important after Early Diagnosis of Alzheimer’s Disease from the Perspectives of People with Alzheimer’s Disease, Spouses and Professionals?
  • Chapter 10
    Potential Repurposing of Oncology Drugs for the Treatment of Alzheimer’s Disease
Readership: Students, academics, teachers and other people attending or interested in Advances in Alzheimer's Disease
Michael W. Beckett
School of Kinesiology and Health Science, York University, Toronto, Canada

Katharina Stoeck
Department of Neurology, Clinical Dementia Centre, DZNE and National Reference Centre for Human Prion Diseases, University Medical Center, G?ttingen, Germany

Kenichi Meguro
Division of Geriatric Behavioral Neurology, CYRIC, Tohoku University, Sendai, Japan

Michelle T. Fodero-Tavoletti
the Florey Institute of Neuroscience and Mental Health, Parkville, Melbourne, Victoria, Australia

Sachin S. Tiwari
Centre for Cellular Basis of Behaviour, Department of Neuroscience, King’s College London, London, UK

Barbara Plagg
Laboratory of Psychiatry and Experimental Alzheimer’s Research, Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Innsbruck, Austria

and more...
Copyright © 2006-2022 Scientific Research Publishing Inc. All Rights Reserved.
Top